Breakthrough disease during interferon-β therapy in MS

• DOI: 10.1212/wnl.0b013e3181dc1a94
• Publication Date: 2010-05-03T20:35:52Z
• Authors: D. Hesse; M. Krakauer; H. Lund; H.B. Søndergaard; A. Langkilde; L.P. Ryder; P.S. Sorensen; F. Sellebjerg
• Keywords: Subclinical infection

Disease activity is highly variable in patients with multiple sclerosis (MS), both untreated and during interferon (IFN)-beta therapy. Breakthrough disease often regarded as treatment failure; however, apart from neutralizing antibodies (NAbs), no blood biomarkers have been established reliable indicators of response, despite substantial, biologically measurable effects. We studied the biologic response to a cohort NAb-negative test whether difference responsiveness could segregate without breakthrough therapy.Gene expression cells 23 relapsing-remitting MS was analyzed by microarray PCR. Samples were collected pretreatment 9-12 hours after IFNbeta injection at 3 6 months' treatment. Definition based on occurrence relapses, disability progression, or subclinical 3T MRI months.Sixteen had 7 stable. Microarray PCR showed marked effects gene profiles, but responses did not differ between stable patients. However, variables differ: lower baseline IL10 expression, more gadolinium-enhancing lesions, higher number volume T2 lesions.Breakthrough paralleled differences patients; most likely, spontaneously occurring variation underlying causes varying level observed IFNbeta-treated sclerosis.